{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Rate of Very Good Partial Response (VGPR), Complete Response (CR) and Stringent Complete Response (sCR)","groups":[{"description":"Revlimid, Velcade, dexamethasone and Farydak","id":"OG000","title":"Arm 1 - RVD + Pan"},{"description":"Revlimid, Velcade and Dexamethasone","id":"OG001","title":"Arm 2 - RVD"}],"populationDescription":"The study was terminated prematurely and because only 6 patients were enrolled, efficacy data were not evaluated.","reportingStatus":"POSTED","timeFrame":"Day 22 up to end of study, approximately 3 years","title":"Depth of Response by International Myeloma Working Group (IMWG) Criteria","type":"SECONDARY"}